BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061G951. A total of 4 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,672,052 | +82.7% | 53,900 | +104.9% | 0.00% | – |
| Q1 2023 | $2,557,000 | +93838.3% | 26,300 | 0.0% | 0.00% | – |
| Q4 2022 | $2,722 | -99.9% | 26,300 | -47.4% | 0.00% | -100.0% |
| Q2 2022 | $4,144,000 | +27526.7% | 50,000 | +24900.0% | 0.00% | – |
| Q1 2022 | $15,000 | -99.6% | 200 | -99.6% | 0.00% | -100.0% |
| Q1 2021 | $3,776,000 | -66.6% | 50,000 | -61.2% | 0.00% | -50.0% |
| Q4 2020 | $11,294,000 | +64.2% | 128,800 | +42.3% | 0.00% | +100.0% |
| Q3 2020 | $6,878,000 | +37.7% | 90,500 | +123.5% | 0.00% | 0.0% |
| Q2 2020 | $4,995,000 | +118.8% | 40,500 | +50.0% | 0.00% | – |
| Q4 2019 | $2,283,000 | +125.8% | 27,000 | +80.0% | 0.00% | – |
| Q3 2019 | $1,011,000 | -90.0% | 15,000 | -87.5% | 0.00% | -100.0% |
| Q2 2019 | $10,084,000 | -59.1% | 120,000 | -58.5% | 0.00% | -66.7% |
| Q4 2018 | $24,634,000 | +132.4% | 289,300 | +164.7% | 0.01% | +200.0% |
| Q3 2018 | $10,599,000 | +2.3% | 109,300 | -0.6% | 0.00% | 0.0% |
| Q2 2018 | $10,362,000 | +155.6% | 110,000 | +120.0% | 0.00% | +100.0% |
| Q1 2018 | $4,054,000 | -9.1% | 50,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $4,459,000 | +34.6% | 50,000 | +25.0% | 0.00% | 0.0% |
| Q4 2016 | $3,314,000 | -14.8% | 40,000 | -20.0% | 0.00% | 0.0% |
| Q2 2016 | $3,890,000 | – | 50,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Maven Securities LTD | 10,000 | $834,000 | 0.03% |
| GROUP ONE TRADING, L.P. | 241,100 | $20,117,000 | 0.02% |
| SIMPLEX TRADING, LLC | 94,500 | $7,885,000 | 0.01% |
| IMC-Chicago, LLC | 49,200 | $4,105,000 | 0.01% |
| WELLS FARGO & COMPANY/MN | 47,200 | $3,935,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |